Subtype Report: Marginal Zone Lymphoma
Under the banner of MZL are EMZL, NMZL and SMZL despite the fact that their clinical and molecular characteristics are distinct from each other. A clearer understanding of the genomics of the subgroups of MZL as well as improved data regarding biological markers can help improve patient diagnosis and outcomes.
MZL has a distinct lack of large databases, clinical data and standard of care. There needs to be a more concentrated effort to increase clinical trials for MZL patients in order to analyse the efficacy of treatments. By working together and collaborating, national and international research groups have an opportunity to create a more tailored and relevant treatment protocol.
Globally, patient access to care is often incomplete and sporadic. There are regional differences where access to novel and recommended therapies is not universal. With this information, the lymphoma community and LC members can work together to find solutions to gain broader access for patients. Having said that, the first step should be supporting research in developing a best practice for treatment of MZL.
Click here to view or download the report.